Fomivirsen

From Wikipedia, the free encyclopedia


Fomivirsen
Systematic (IUPAC) name
?
Identifiers
CAS number	160369-77-7
ATC code	S01AD08
PubChem	?
Chemical data
Formula	C₂₀₄H₂₆₃N₆₃O₁₁₄P₂₀S₂₀
Mol. mass	6682.4 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	B2
Legal status
Routes	Intravitreal injection

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS.

It is an oligonucleotide that blocks translation of viral mRNA by binding to a coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.^[1]

It is available as an intraocular injection in a concentration of 6.6 mg/ml^[2]

[edit] References

^ Roush, W. 1997. Antisense aims for a renaissance. Science 276: 1192-93
^ Katzung, BG. Basic and Clinical Pharmacology 10th ed., 2007. McGraw-Hill Co., Inc.

[edit] See also

retinitis

[edit] External links

Diagram
MedlinePlus DrugInfo uspdi-203675
DDB 31313
"Fomivirsen." (2001). Drugs Today (Barc) 37 (4): 245–255. PMID 12768225.
Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions.". Clin Pharmacokinet 41 (4): 255–60. PMID 11978144.
"Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS." (2002). Am J Ophthalmol 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781.
Roehr B (1998). "Fomivirsen approved for CMV retinitis.". J Int Assoc Physicians AIDS Care 4 (10): 14–6. PMID 11365956.